TatianaMichelleProwellMD

PubMed

• 172 citations
  FDA Approval Summary: Temsirolimus as Treatment for Advanced Renal Cell Carcinoma
  Virginia E. Kwitkowski, Tatiana M. Prowell, Amna Ibrahim, Ann T. Farrell, Robert Justice
  The Oncologist. 2010-04-01
• 180 citations
  CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled a...
  Jennifer J Gao, Joyce Cheng, Erik Bloomquist, Jacquelyn Sanchez, Suparna Wedam
  The Lancet. Oncology. 2020-02-01
• 2838 citations
  Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
  Patricia Cortazar, Lijun Zhang, Michael Untch, Keyur Mehta, Joseph P. Costantino
  Lancet. 2014-07-12

Books/Book Chapters

• Breast Cancer Management and Molecular Medicine: Towards Tailored Approaches 
  Chapter: Metastatic breast cancer: Tailored endocrine therapy for premenopausal women. 
  Page 445 - 458Prowell T, Davidson NEditors: Piccart M, Wood W, Hung M-C, Solin L, Cardoso F..Springer-Verlag2006
• The Osler Medical Handbook 
  Chapter: Neutropenic Fever. 
  Page 537 - 544Prowell T, Smith BEditors: Cheng A, Zaas A..Mosby, Philadelphia, PAEdition Firs,2003
• The Osler Medical Handbook 
  Chapter: Asthma. 
  Page 867 - 880Prowell T, Liu MEditors: Cheng A, Zaas A..Mosby, Philadelphia, PAEdition Firs,2003

Abstracts/Posters

• A Definition of a High-Risk Early-Breast Cancer Population Based on Data from the Collaborative Trials in Neoadjuvant Breast Cancer (CTNeoBC) meta-analysis.
  Cortazar P, Zhang L, Untch M, Mehta K, Costantino J, Wolmark N, Bonnefoi H, Cameron D, Gianni L, Valagussa P, Zujewski J, Justice R, Loibl S, Wickerham L, Bogaerts J, ..., Cancer Res, 1/1/2013
• Meta-analysis Results from the Collaborative Trials in Neoadjuvant Breast Cancer (CTneoBC).
  Cortazar P, Zhang L, Untch M, Mehta K, Costantino J, Wolmark N, Bonnefoi H, Cameron D, Gianni L, Valagussa P, Zujewski J, Justice R, Loibl S, Wickerham L, Bogaerts J, ..., Cancer Res

Lectures

• Seeking New Opportunities: What to Look for and How to Prepare for Them 
  2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
• "Pathological Complete Response: Is It the Holy Grail?" 
  Baltimore, MD - 3/7/2014
• Grand Rounds: "Preoperative Systemic Therapy for Breast Cancer: Considerations for Investigators, Clinicians, and Patients." 
  Norris Cotton Cancer Center, Dartmouth-Hitchcock Medical Center, Hanover, NH - 2/18/2014
• "Ethics of Oncology Drug Development: Trial Design, Compassionate Use of Investigational Agents, and Drug Pricing." 
  2/12/2014
• "Compassionate Use of Investigational Agents." 
  Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD - 12/18/2013
• "Pertuzumab for High-Risk, Early Breast Cancer." 
  Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD - 11/20/2013
• "Implementation of the Final Guidance on Accelerated Approval in the Neoadjuvant Setting." 
  Washington, DC - 11/15/2013
• "Understanding the U.S. FDA Guidance on Pathological Complete Response and Accelerated Approval" 
  Chicago, IL - 6/1/2013
• "Impact of Phase I Trials on Safety and Optimal Dose for Future Clinical Practice." 
  Chicago, IL - 6/1/2013
• "Clinical Trials with Molecular Selection: Neoadjuvant Trial Design." 
  Chicago, IL - 5/30/2013
• "Drug-Induced Peripheral Neuropathy in Cancer Patients." 
  Silver Spring, MD - 4/11/2013
• Panel Discussion: "The Promise and Challenges of Pathological Complete Response (pCR) as a Novel Endpoint for Drug Approval in High-Risk, Early-Stage Breast Cancer." 
  Washington, DC - 4/8/2013
• "Considerations for Neoadjuvant Breast Cancer Trials to Support Accelerated Approval." 
  Silver Spring, MD - 3/22/2013
• "Oncology Drug Development: A Regulatory Perspective." 
  Dana Farber Cancer Institute, Boston, MA - 3/5/2013
• Grand Rounds: "Exploiting the Preoperative Setting: Streamlining Drug Development in High-Risk, Early Stage Breast Cancer." 
  Internal Medicine, Johns Hopkins Hospital, Baltimore, MD - 1/4/2013
• "Pathological Complete Response as an Endpoint to Support Accelerated Approval in High-Risk, Early-Stage Breast Cancer." 
  Mt. Sinai School of Medicine, New York, NY - 11/8/2012
• "Strategies to Expedite Oncology Drug Development." 
  Silver Spring, MD - 11/7/2012
• Grand Rounds: "Oncology Drug Development: A Regulatory Perspective." 
  Medical Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD - 6/22/2012
• "Pathologic Complete Response as an Endpoint to Support Accelerated Approval" 
  Chicago, IL - 6/1/2012
• "Emerging Concepts of Drug Safety in Oncology" 
  Chicago, IL - 6/1/2012
• "Pitfalls in Oncology Drug Development." 
  Bethesda, MD - 5/16/2012
• "Meet the Professor Session: Breast Cancer." 
  Johns Hopkins University School of Medicine, Baltimore, MD - 5/9/2012
• "Are Anthracyclines Past Their Prime?" 
  Annapolis, MD - 3/30/2012
• "Regulatory Considerations in Oncology Drug Development." 
  Dana Farber Cancer Institute. Boston, MA - 3/5/2012
• "Clinical Trials Versus Standard of Care." 
  Baltimore, MD - 10/29/2011
• Join now to see all

Other

• Guidance for Industry: Pathologic Complete Response in Neoadjuvant Treatment of High-Risk Early-Stage Breast Cancer: Use as an Endpoint to Support Accelerated Approval 
  Prowell T
  http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM305501.pdf
• "Accelerating the Search for Breast Cancer Therapies for Triple Negative Breast Cancer." 
  Tatiana Michelle Prowell, MD, CBS Biocentury TV
  Washington, DC - 7/29/2012
• Webinar: "Draft Guidance on Using Pathologic Complete Response as an Endpoint to Support Accelerated Approval of Drugs to Treat Early-Stage Breast Cancer." 
  Tatiana Michelle Prowell, MD
  Office of Medical Policy, Center for Drug Evaluation and Research, Food & Drug Administration, Silve - 6/28/2012
• "FDA and Cancer: The Inside View." 
  Tatiana Michelle Prowell, MD, CBS Biocentury TV
  Washington, DC - 2/5/2012
• Commentary on: "Are breast density and bone mineral density independent risk factors for breast cancer?" (Kerlikowske et al, J Natl Cancer Inst 2005;97:368-374). 
  Prowell T, Stearns V, The North America Menopausal Society (NAMS): First to Know
  http://www.menopause.org/news.html
  4/1/2005
• Join now to see all